Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics

Autor: Michael Mckenna, Sarah Hamren, Mickey S. Urdea, Theodore M. Tarasow, Anil Patwardhan, Laura Penny

Publikováno v: Bioanalysis. 3:2233-2251

Complex diseases are caused by combinatorial genetic, environmental and lifestyle factors. The emergence of multibiomarker tests to define these diseases and to identify the early, presymptomatic stages offers several advantages to the conventional u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d8b9d74e9fe8d7837d8f4ae9c7e078d
https://doi.org/10.4155/bio.11.224

Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line

Autor: Steve Roczniak, Sarah Hamren, Irene Tom, Clark Q. Pan, Mary DeRome

Publikováno v: Peptides. 29:479-486

Vasoactive intestinal peptide (VIP) binds to two receptors, VPAC1 and VPAC2. Non-selective VIP antagonists have been shown to inhibit human cancer cell proliferation and reduce tumor growth in mice. Many human cancers over-express VPAC1 but not VPAC2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4696d8a75e659bd44739d87a38d256fd
https://doi.org/10.1016/j.peptides.2007.09.003

Abstract P014: Clinically Significant Novel Biomarkers for Prediction of First-ever Myocardial Infarction-The Tromsø Study

Autor: Tom Wilsgaard, Ellisiv B Mathiesen, Henrik Schirmer, Maja-Lisa Lochen, Kaare H Bonaa, Sarah Hamren, Michael W Rowe, Julie Sudduth-Klinger, Anil Patwardhan, Inger Njolstad

Publikováno v: Circulation. 129

Background: Identification of individuals with high risk for first-ever myocardial infarction (MI) can be improved. The objectives of the study ere to survey multiple protein biomarkers for association with the 5-year risk of incident MI and identify

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aee144ca90e37ecc42263f5504f1ea4
https://doi.org/10.1161/circ.129.suppl_1.p014

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort

Autor: Janice A. Kolberg, Michael Rowe, Oluf Pedersen, Mickey S. Urdea, Xiaomei M. Xu, Knut Borch-Johnsen, Torben Jørgensen, Torben Hansen, Sarah Hamren, Michael Mckenna, Edward Moler, Robert W. Gerwien

Publikováno v: Kolberg, J A, Jørgensen, T, Gerwien, R W, Hamren, S, McKenna, M P, Moler, E, Rowe, M W, Urdea, M S, Xu, X M, Hansen, T, Pedersen, O & Borch-Johnsen, K 2009, ' Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort ', Diabetes Care, vol. 32, no. 7, pp. 1207-12 . https://doi.org/10.2337/dc08-1935

OBJECTIVE The purpose of this study was to develop a model for assessing the 5-year risk of developing type 2 diabetes from a panel of 64 circulating candidate biomarkers. RESEARCH DESIGN AND METHODS Subjects were selected from the Inter99 cohort, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23150886769f6efd40534c984bdb0892
https://portal.findresearcher.sdu.dk/da/publications/99430110-bfb3-11de-9bfd-000ea68e967b

A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes

Autor: Manami, Tsutsumi, Thomas H, Claus, Yin, Liang, Yaxin, Li, Ling, Yang, Jian, Zhu, Fernando, Dela Cruz, Xianbu, Peng, Hongxing, Chen, Stephanie L, Yung, Sarah, Hamren, James N, Livingston, Clark Q, Pan

Publikováno v: Diabetes. 51(5)

Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) activate two shared receptors, VPAC1 and VPAC2. Activation of VPAC1 has been implicated in elevating glucose output, whereas activation of VPAC2 may be inv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8bde22b88490e1db93934510f8c5a4cf
https://pubmed.ncbi.nlm.nih.gov/11978642